EdgeMarket › What Rhenman & Partners Asset Management Ab reported owning
What Rhenman & Partners Asset Management Ab reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
810.5MPositions
86Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| BSX BOSTON SCIENTIFIC CORP | 39.2M | 4.8% | 625.0K | 50.37 | -52.5% |
| REGN REGENERON PHARMACEUTICALS, INC. | 37.2M | 4.6% | 48.1K | 834.04 | +41.1% |
| LLY ELI LILLY & Co | 31.0M | 3.8% | 33.7K | 1,255.40 | +78.0% |
| INSM INSMED Inc | 26.1M | 3.2% | 159.8K | 125.77 | -2.8% |
| CVS CVS HEALTH Corp | 24.2M | 3.0% | 336.5K | 93.02 | +31.3% |
| GILD GILEAD SCIENCES, INC. | 23.4M | 2.9% | 167.8K | 146.12 | +23.1% |
| TMO THERMO FISHER SCIENTIFIC INC. | 20.3M | 2.5% | 41.3K | 629.27 | +27.2% |
| BIIB BIOGEN INC. | 20.0M | 2.5% | 109.1K | 216.78 | +56.0% |
| VRTX VERTEX PHARMACEUTICALS INC / MA | 19.4M | 2.4% | 43.5K | 548.05 | +39.0% |
| ALHC Alignment Healthcare, Inc. | 18.6M | 2.3% | 1.1M | 13.16 | -12.4% |
| ISRG INTUITIVE SURGICAL INC | 17.0M | 2.1% | 36.8K | 378.81 | -21.2% |
| COR Cencora, Inc. | 16.5M | 2.0% | 52.4K | 318.04 | +4.7% |
| SYK STRYKER CORP | 15.7M | 1.9% | 47.8K | 329.45 | -15.9% |
| ABBV AbbVie Inc. | 15.6M | 1.9% | 71.6K | 264.96 | +26.7% |
| VEEV VEEVA SYSTEMS INC | 15.0M | 1.8% | 85.3K | 247.90 | -12.7% |
| MCK MCKESSON CORP | 14.6M | 1.8% | 16.9K | 858.90 | +22.2% |
| JAZZ Jazz Pharmaceuticals plc | 14.3M | 1.8% | 75.9K | 254.28 | +113.6% |
| GH Guardant Health, Inc. | 13.4M | 1.7% | 145.0K | 170.69 | +191.8% |
| NBIX NEUROCRINE BIOSCIENCES INC | 13.3M | 1.6% | 100.8K | 152.57 | +14.5% |
| EW Edwards Lifesciences Corp | 13.1M | 1.6% | 163.0K | 89.79 | +10.3% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 12.6M | 1.6% | 24.1K | 516.74 | +31.9% |
| UNH UNITEDHEALTH GROUP INC | 12.3M | 1.5% | 45.5K | 390.11 | +30.1% |
| PRCT PROCEPT BioRobotics Corp | 11.9M | 1.5% | 475.0K | 21.68 | -44.9% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 11.7M | 1.4% | 207.0K | 66.70 | +15.1% |
| ABT ABBOTT LABORATORIES | 11.5M | 1.4% | 112.0K | 116.64 | -11.9% |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | 11.4M | 1.4% | 34.5K | 236.22 | -48.5% |
| RPRX Royalty Pharma plc | 11.2M | 1.4% | 233.0K | 61.31 | +66.2% |
| AXSM Axsome Therapeutics, Inc. | 10.8M | 1.3% | 63.8K | 207.77 | +77.6% |
| NTRA Natera, Inc. | 10.3M | 1.3% | 51.6K | 332.03 | +106.7% |
| THC TENET HEALTHCARE CORP | 10.2M | 1.3% | 54.0K | 280.77 | +54.3% |
| ADPT Adaptive Biotechnologies Corp | 10.0M | 1.2% | 720.0K | 25.99 | +111.4% |
| LIVN LivaNova PLC | 9.9M | 1.2% | 155.0K | 78.74 | +47.5% |
| ELV Elevance Health, Inc. | 9.5M | 1.2% | 32.3K | 400.54 | +29.2% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 9.1M | 1.1% | 144.5K | 87.11 | +331.2% |
| GKOS GLAUKOS Corp | 9.0M | 1.1% | 84.0K | 184.89 | +103.3% |
| IQV IQVIA HOLDINGS INC. | 9.0M | 1.1% | 53.0K | 259.82 | +35.3% |
| SNDX Syndax Pharmaceuticals Inc | 8.9M | 1.1% | 379.2K | 19.65 | +24.8% |
| MIRM Mirum Pharmaceuticals, Inc. | 8.6M | 1.1% | 92.6K | 96.31 | +44.4% |
| IDYA IDEAYA Biosciences, Inc. | 8.5M | 1.1% | 255.5K | 39.67 | +63.1% |
| PNTG Pennant Group, Inc. | 8.4M | 1.0% | 275.4K | 38.88 | +54.5% |
| unmapped CUSIP 670703107 | 8.3M | 1.0% | 81.2K | — | — |
| WAY Waystar Holding Corp. | 8.3M | 1.0% | 342.6K | 25.01 | -28.7% |
| AVR Anteris Technologies Global Corp. | 8.0M | 1.0% | 1.4M | 8.98 | +152.2% |
| MDT Medtronic plc | 7.8M | 1.0% | 90.0K | 93.35 | +0.1% |
| OSCR Oscar Health, Inc. | 7.6M | 0.9% | 660.0K | 32.04 | +109.8% |
| IOVA IOVANCE BIOTHERAPEUTICS, INC. | 7.2M | 0.9% | 2.1M | 8.29 | +227.7% |
| MLYS Mineralys Therapeutics, Inc. | 7.1M | 0.9% | 263.1K | 25.65 | +65.7% |
| IONS IONIS PHARMACEUTICALS INC | 7.0M | 0.9% | 92.9K | 59.74 | +39.5% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 6.9M | 0.8% | 81.6K | 111.10 | +374.4% |
| BBIO BridgeBio Pharma, Inc. | 6.7M | 0.8% | 90.6K | 81.50 | +66.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →